Breast Cancer

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.

Among women with nonmetastatic breast cancer, obesity was associated with poorer outcomes only among those with luminal A cancers based on PAM50 gene expression analysis, according to a new study.

A database analysis found that facility-level factors such as location contribute more than patient-level factors to the underuse of guideline-recommended therapy for nonmetastatic inflammatory breast cancer.

A new population-based study is suggesting that there are significant racial disparities in gene expression profiling testing in women with breast cancer.

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells-to fight tumors rather than encourage growth-caused breast tumors in mice to shrink and withdraw from distant metastases.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

Breast conservation therapy is usually best for local treatment for stage II breast cancer-and biology, as well as stage, drives patient outcomes.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma-cancers in which immunotherapy have shown particular promise-breast cancers are nevertheless immunogenic.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.

Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.

Timing remains an important challenge for breast reconstruction in patients undergoing radiation therapy and surgery for breast cancer.

Recent findings have raised doubts about the promise of whole-brain radiation therapy against metastatic brain tumors for patients with advanced breast cancer.

Breast surgeons can and should provide genetic counseling to their patients because the need outstrips the availability of genetic counselors.

We spoke with breast imaging radiologist Dr. Elizabeth Morris on imaging vigilance for women at high risk of developing breast cancer.

A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.

Some women with breast cancer may survive longer if they consume soy-based foods, according to a new study.

Scientists have discovered that African American patients with triple-negative breast cancer who carry a specific biomarker, nKIFC1, experience a dismal prognosis.

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism.

In patients with breast cancer with a recurrence score based on a 21-gene expression assay of 11 to 25, outcomes were similar whether chemotherapy was used or not.

Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens.

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

We know that breast cancer represents a spectrum of diseases, with variation in prognosis, and that RT can range from highly complex treatments to the breast and regional lymph nodes, to complete avoidance of radiation.